Literature DB >> 24276187

[Neuroendocrine differentiation in prostate adenocarcinoma].

Lázaro Ramírez-Balderrama1, Sergio López-Briones, Leonel Daza-Benítez, Maciste H Macías, Teresa López-Gaytán, Victoriano Pérez-Vázquez.   

Abstract

The human prostate is a gland composed of many types of cells and extracellular components with specific functions. The stromal compartment includes nerve tissue, fibroblasts, lymphocytes, macrophages, endothelial cells, and smooth muscular cells. The epithelial compartment is composed of luminal epithelial cells, basal cells, and a lesser number of neuroendocrine cells, which are transcendental in growth regulation, differentiation, and secretory function. In prostate cancer, neuroendocrine cells replicate especially in high grade and advanced stage, and hormonally treated tumoral cells adopt characteristics that make them resistant to hormonal deprivation. Androgen receptors have a crucial role in tumorigenesis of prostate adenocarcinoma. Deprivation hormone therapy blocks the expression of androgen receptors in the prostatic epithelial cells. Neuroendocrine cells lack androgen receptors; their growth is hormonally independent and that is why deprivation hormonal therapy does not eliminate the neoplasic neuroendocrine cells. In contrast, these types of cells proliferate after therapy and make a paracrine network, stimulating the proliferation of androgen-independent neoplastic cells, which finally lead to tumoral recurrence. In this work we describe the neuroendocrine function in normal tissue and in prostatic adenocarcinoma, including neoplasic proliferation stimulation, invasion, apoptosis resistance, and angiogenesis, and describe some molecular pathways involved in this neuroendocrine differentiation.

Entities:  

Mesh:

Year:  2013        PMID: 24276187

Source DB:  PubMed          Journal:  Gac Med Mex        ISSN: 0016-3813            Impact factor:   0.302


  1 in total

1.  Rapid progression of mixed neuroendocrine carcinoma-acinar adenocarcinoma of the prostate: A case report.

Authors:  Jingchao Wei; Xiaoping Zheng; Liuxun Li; Wensu Wei; Zhi Long; Leye He
Journal:  Oncol Lett       Date:  2016-06-16       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.